- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00962221
Lipids Profile in Subclinical Hypothyroidism (LPSH)
Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overt hypothyroidism is associated with increased risk for cardiovascular disease[CVD] as indicated by hypertension, hypercholesterolemia, and increased low-density lipoprotein cholesterol (LDL-C) levels.However, not all patients have hypertension or abnormal lipid profiles, suggesting that other factors may be involved as collagen-induced platelet aggregation or relaxation of vascular smooth muscle, elevated plasma homocysteine and C- reactive protein [CRP] levels have been reported in overt hypothyroidism and have been proposed as an independent risk factor for CVD.
Subclinical hypothyroidism [SH] is highly prevalent in elderly subjects, especially in women older than 50 years of age. Whether SH is related as a risk for premature CVD is controversial. Previously, we have demonstrated that SH in middle-aged women is associated with hypertension, hypertriglyceridemia, and elevated total cholesterol/HDL- cholesterol ratio.SH was associated with elevated plasma total cholesterol and LDL-cholesterol, decreased LDL-cholesterol/LDL-triglycerides due to decreased hepatic lipase activity. The influence of SH on lipids was directly proportional to the degree of TSH elevation.
Atherosclerosis is a diffuse disease formerly considered lipid storage disease, actually involves an ongoing inflammatory response. Elevated circulating levels of acute phase proteins, cytokines, and cell adhesion molecules indicate that inflammatory processes are occurring systematically. Metabolic syndrome is a collection of metabolic risk factors, probably of more than one cause, that appear to promote the development of atherosclerotic CVD. Hypertension, dyslipidemia and hyperglycemia are the most widely recognized characteristics of the metabolic syndrome. Individuals with metabolic syndrome manifest a prothrombotic state as well as a proinflammatory state. Insulin resistance is recognized as a chronic low-level inflammatory state. Insulin action is an important effector mechanism of the proinflammatory cytokines in CVD. Insulin resistance was proposed as the common preceding factor of hypertension, LDL and HDL-cholesterol, hypertriglyceridemia, abdominal obesity and altered glucose metabolism, linking all of these to the development of CVD. Thus, inflammation, metabolic syndrome and insulin resistance are strongly associated and play an important role in the pathogenesis of atherosclerosis. In a cross-sectional analysis, subjects with SH had a significantly higher prevalence of CVD than euthyroid subjects. There were more cardiovascular deaths in subjects with SH than in the euthyroid population. These data suggest that SH may be an independent risk factor for CVD. It is not clear yet whether patients with SH have cardiovascular risk, as do patients with overt hypothyroidism, and whether metabolic syndrome and insulin resistance already exist in untreated patients with SH.
This question was recently studied by our group. We evaluated untreated patients with SH. the percentage of MS in patients (41.5%) was significantly higher than in controls (12.2%; p=0.003]. SH had significantly higher likelihood of cardiovascular risks [odds ratio 6.26, 95% confidence interval (CI) 1.6 - 4.49, p= 0.008 for MS].
We conclude that SH is associated with greater probability of MS. Recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL exerts a direct influence on the cardiovascular risk. LDL comprises multiple distinct subclasses that differ in size, density, physicochemical composition, metabolic behaviour and atherogenicity. There are at least four major subspecies of LDL (e.g. large LDL-I, medium LDL-II, small LDL-III, very small LDL-IV) and the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor.
Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with subclinical Hypothyroidism.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Afula, Israel, 18101
- Endocrine Institute, Haemek Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects with subclinical hypothyroidism
Exclusion Criteria:
- Patients taking L-thyroxin therapy
- Patients with known cardiovascular, cerebral or peripheral atherosclerotic disease.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
subclinical hypothyroidism
Patients with subclinical hypothyroidism
|
laboratory analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of atherogenic lipoproteins
Time Frame: enrollment
|
enrollment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0099.09EMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subclinical Hypothyroidism
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemCompletedSubclinical HypothyroidismUnited States
-
AbbottDimension ResearchCompletedSubclinical HypothyroidismPakistan
-
Assaf-Harofeh Medical CenterCompleted
-
Cooperativas Lacteas UnidasGalician South Health Research InstituteNot yet recruitingSubclinical HypothyroidismSpain
-
Peking Union Medical College HospitalBeijing Municipal Science & Technology CommissionCompletedSubclinical HypothyroidismChina
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | Subclinical Hypothyroidism | HypothyroxinemiaUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedSubclinical HypothyroidismUnited States
-
Sohag UniversityNot yet recruitingSubclinical Hypothyroidism
-
HaEmek Medical Center, IsraelCompletedHyperthyroidism | Subclinical Hypothyroidism | Thyroid DysfunctionIsrael
-
NHS Greater Glasgow and ClydeUniversity of Bern; Leiden University Medical Center; University College Cork; University...CompletedSubclinical HypothyroidismUnited Kingdom
Clinical Trials on laboratory analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
HaEmek Medical Center, IsraelCompleted
-
European Society of Cutaneous Lupus Erythematosus...UnknownLupus Erythematosus, Systemic | Lupus Erythematosus, CutaneousGermany
-
European Society of Cutaneous Lupus Erythematosus...Completed
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCTerminatedLymphoma | Nonneoplastic ConditionUnited States
-
University Hospital OstravaCompletedRhabdomyolysis | Tissue Injury | Major TraumaCzechia
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
China National Center for Cardiovascular DiseasesPeking Union Medical College HospitalRecruiting